Medications to Prevent Hypomania in Bipolar II Disorder
Lithium or lamotrigine should be your first-line maintenance medications to prevent hypomanic episodes in Bipolar II disorder, with lithium being the gold standard if monitoring is available, and lamotrigine being particularly effective for preventing the depressive episodes that dominate this condition.
Primary Maintenance Treatment Options
First-Line Agents
Lithium remains the most evidence-based option for preventing both hypomanic and depressive recurrences 1, 2. It is FDA-approved for maintenance therapy and has the strongest overall prophylactic efficacy, particularly for preventing manic/hypomanic episodes 3, 4. However, lithium requires regular laboratory monitoring (renal function, thyroid, serum levels) and is only appropriate when such monitoring infrastructure exists 1.
Lamotrigine has emerged as an excellent alternative, with particularly strong evidence in Bipolar II disorder specifically. A 2017 study demonstrated that lamotrigine may actually be more suitable for maintenance treatment in Bipolar II than Bipolar I, showing significantly longer time to recurrence/relapse of mood episodes in Bipolar II patients 5. Lamotrigine is FDA-approved for maintenance therapy in adults and appears to "stabilize mood from below baseline" by primarily preventing depressive episodes 4, which is crucial since Bipolar II patients experience depressive episodes at a 39:1 ratio compared to hypomanic episodes 6.
Second-Line Agents
Valproate (divalproex) is recommended for maintenance treatment, though the controlled data is less robust than for lithium 1. It can be effective for preventing hypomanic recurrences but evidence is more limited 4.
Atypical antipsychotics, particularly quetiapine and olanzapine, have demonstrated efficacy in maintenance treatment 7, 4. These showed the strongest evidence among antipsychotics for long-term prevention, either as monotherapy or combined with lithium/divalproex 7. However, metabolic side effects (weight gain, diabetes risk) are significant concerns 8.
Treatment Algorithm
If laboratory monitoring is readily available: Start with lithium as it has the broadest prophylactic effect against both poles
If monitoring is limited or patient has contraindications to lithium: Use lamotrigine, which has specific evidence in Bipolar II and targets the predominant depressive burden 5, 9
If rapid cycling or mixed features are present: Consider valproate or combination therapy 7
For treatment-resistant cases: Add an atypical antipsychotic (quetiapine or olanzapine) to the mood stabilizer 7, 4
Critical Caveats
Avoid antidepressant monotherapy—this is a common and dangerous pitfall. Antidepressants can destabilize mood and precipitate hypomanic episodes 3. If antidepressants are needed for severe depression, they must always be combined with a mood stabilizer (lithium or valproate), with SSRIs preferred over tricyclics 1.
Maintenance treatment should continue for at least 2 years after the last mood episode 1. Given that Bipolar II is often misdiagnosed as major depression and undertreated, early recognition and sustained prophylactic treatment are essential to prevent the significant functional impairment and elevated suicide risk associated with this condition 6, 8.
Monotherapy is often insufficient long-term—most patients eventually require combination therapy to maintain full remission 4. However, avoid unnecessary polypharmacy by starting with a single evidence-based agent and adding only when clinically indicated.
The choice between lithium and lamotrigine should be guided by: (1) availability of monitoring, (2) whether preventing hypomania or depression is the greater clinical priority, (3) side effect tolerability, and (4) patient/family history of medication response 3.